RecipientAmountDeal/Technology HighlightLead InvestorsDeal TypeCountry
Loxo Oncology$1,550 millionTo develop and commercialize larotrectinib and LOXO-195, Loxo Oncology’s franchise of highly selective TRK inhibitors for patients with TRK fusion cancersBayer AG Collaboration United States
Zymeworks $1,452 millionTo develop and commercialize next generation bispecific antibody therapeuticsJanssen Biotech, IncLicense Agreement Canada
City of London$1,300 millionTo establish a state of the art life sciences discovery research facility in London, focussed on early bioscience discovery and entrepreneurial innovation.MSD (Merck & Co.)InvestmentUnited States
Cardinal Health$1,200 millionCardinal Health, Inc. is a global, integrated healthcare services and products company, providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide. Shanghai Pharmaceuticals Holding Co., LtdAcquisition of China BusinessUnited States
PeptiDream $1,110 millionPeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology to identify macrocyclic/constrained peptides against multiple targetsBayer AG Collaboration Japan
H. D. Smith$815 millionAcquisition of U.S.’s Largest Independent Wholesaler Enhances & Expands Strategic Scale, Strengthens Support to Community Pharmacy and Drives Long-Term, Durable ValueAmerisourceBergen AcquisitionUnited States
Principia Biopharma Inc.$805 millionSanofi will develop Principia's Bruton's tyrosine kinase (BTK) inhibitor (PRN2246), a multiple sclerosis drug candidateSanofi License Agreement United States
Ionis Pharmaceuticals, Inc.$805 millionIONIS-JBI2-2.5Rx is designed to locally reduce the production of an undisclosed target in the gastrointestinal (GI) tract for the treatment of a GI autoimmune disease.Janssen Biotech, IncCollaboration United States
CVS Health Corporation$735 millionTo acquire RxCrossroads a provider of tailored services to pharmaceutical and biotechnology manufacturersMcKesson CorporationAcquisition of BusinessUnited States
Halyard Health, Inc.$710 millionS&IP provides healthcare supplies and solutions that target the prevention of healthcare-associated infections. Owens & Minor, Inc.Acquisition of S&IP BusinessUnited States
Arvinas LLC>$650 millionDevelopment of new therapeutics using Arvinas’ novel PROTAC technologyGenentech License Agreement United States
Bluebird bio$600 millionTo develop potentially transformative gene therapies for severe genetic diseases and cancerIPO FundingUnited States
Unichem Laboratories Limited$558 millionUnichem’s India business comprises of a portfolio of more than 120 brands in India and NepalTorrent Pharmaceuticals LimitedAcquisition of PortfolioIndia
Boehringer Ingelheim$502 millionTo develop, manufacture and commercialize BI 882370, a 2nd-generation RAF inhibitorXynomic PharmaExclusive Global RightsGermany
Mitobridge, Inc.$450 millionTo accelerate the Discovery and Development of Novel Drugs that Target nMitochondrial FunctionsAstellas Pharma Inc. AcquisitionUnited States
MiNA Therapeutics$360 millionTo develop novel treatment approaches for fibrotic liver diseases Boehringer IngelheimCollaboration & License AgreementUnited Kingdom
$280 millionTo continue helping clinical stage ventures improve global health by more rapidly bringing breakthrough medical treatments to market.Aisling CapitalFunding
The Medicines Company$270 millionAcquisition positions Melinta as durable and focused pure-play antibiotics company with four marketed products: Baxdela®, Vabomere®, Orbactiv®, and Minocin IV®Melinta Therapeutics Acquisition of Infectious Disease Business United States
Alkermes $228 millionTo develop and commercialize ALKS 8700 for the treatment of multiple sclerosisBiogenCollaboration & License AgreementRepublic of Ireland
Dicerna$201 millionTo develop novel treatments for chronic liver diseases including nonalcoholic steatohepatitisBoehringer IngelheimCollaboration United States
Valeant Pharmaceuticals $190 millionTo reduced company's total debt by more than $6 billion since the end of the first quarter of 2016Haitong International Zhonghua Finance Acquisition Fund I, L.P., Obagi Cosmeceuticals, LLC.Acquisition of PortfolioCanada
Partners HealthCare System$171.1 millionTo invest in early-stage life sciences companies, which are a critical segment of the state’s innovation economy. The investment strategy will focus exclusively on medical innovations created in the Partners system.Astellas Pharma Inc., Eli Lilly and Company, ShangPharma Corporation etc.FundingUnited States
Xinjiang, China$170 millionFor apocynum fiber “Steam Explosion Degumming” manufacturing, apocynum comprehensive utilization as well as apocynum industry extension projects.Shineco, Inc.Investment
Ardelyx $160 millionTo provides Kyowa Hakko Kirin with exclusive rights to develop and commercialize Ardelyx's lead investigational product, tenapanor for Cardiorenal Diseases in JapanKyowa Hakko KirinExclusive Japan Rights United States
Dimension Therapeutics, Inc.$152.3 millionDimension Therapeutics is developing novel, liver-directed gene therapy treatments for severe, rare genetic disorders.Ultragenyx Pharmaceutical Inc.AcquisitionUnited States
Apellis$150 millionApellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.IPO FundingUnited States
Erytech Pharma$144 millionA clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cellsGlobal OfferingFrance
AstraZeneca$133 millionTo develop and commercialise three potential medicines currently in pre-clinical development from AstraZeneca’s pipeline in its main therapy areas of oncology, cardiovascular and metabolic diseases, and respiratory.Chinese Future Industry Investment Fund (FIIF)Collaboration United Kingdom
MorphoSys $120 millionTo develop and commercialize MOR202 in China, Taiwan, Hong Kong and Macao. MOR202 is MorphoSys’s proprietary investigational antibody against CD38, for which recruitment of a European Phase 1/2a clinical study in relapsed/refractory multiple myeloma has been concluded.I-Mab BiopharmaRegional License AgreementGermany
Ocera Therapeutic$117 millionOcera's developmental product OCR-002, an ammonia scavenger, is being studied for treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia, a complication of acute or chronic liver diseaseMallinckrodt Acquisition United States
Semma Therapeutics$114 millionSemma’s proprietary technologies enable the generation of billions of functional, insulin-producing beta cells which have the potential to control blood sugar in people living with diabetes.Eight Roads Ventures and Cowen Healthcare InvestmentsSeries B FinancingUnited States
Arcus Biosciences$107 millionAdvancement of Arcus’s clinical programs for AB928, a first-in-class dual adenosine receptor antagonist, and AB122, a PD-1 antibodyGV (formerly Google Ventures) & Wellington Management Company LLP etc.Series C FinancingUnited States
Agenus$103 millionFor the advancement of an undisclosed antibody towards the clinic.Merck & Co.Collaboration United States
Portal Instruments$100 millionTo develop the latter's needle-free drug delivery device for potential use with Takeda’s investigational or approved biologic medicines. Takeda Pharmaceutical Company Collaboration United States
BD (Becton, Dickinson and Company)$100 millionThe assets to be acquired are soft tissue core needle biopsy products currently sold by BD under the trade names of Achieve™ Programmable Automatic Biopsy System, Temno™ Biopsy System and Tru-Cut™ Biopsy Needles.Merit Medical Systems, IncAcquisition of AssetsUnited States
scPharmaceuticals$89.6 millionIts platform is focused on providing subcutaneous delivery of commonly used intravenous drugs, allowing convenient at home administration and reducing the cost of hospitalizationIPO FundingUnited States
Oncolytics Biotech® Inc.$86.6 millionOncolytics Biotech is developing REOLYSIN®®, an intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems to turn 'cold' tumors 'hot'Adlai Nortye Regional License AgreementCanada
Codiak BioSciences$76.5 millionTo advance its initial product candidates into clinical trials, and to continue to develop the company’s transformational exosome therapeutic platform.ARCH Venture Partners, Flagship Pioneering, Fidelity Management and Research CompanySeries C FinancingUnited States
Johns Hopkins University$65 millionTo catalyze the development of early stage therapeuticsDeerfield ManagementCollaboration United States
Cambrooke Therapeutics, Inc.$64 millionCambrooke develops and manufactures medical foods for patients with amino acid metabolism disorders and other customers.Ajinomoto Co. Inc.Acquisition United States
Medeor Therapeutics$57 millionTo support the Phase 3 clinical trial of MDR-101 in living donor HLA-matched kidney transplant patients, being conducted under a Special Protocol Agreement with the FDA, as well as a Phase 2b trial of MDR-102 in living donor HLA-mismatched kidney transplant patients.RA Capital ManagementSeries B FinancingUnited States
Xeltis$52 millionTo advance aortic and pulmonary valve programsYsios Capital etcSeries C FinancingSwitzerland
Inozyme Pharma$49 millionTo develop therapies for rare diseases affecting soft tissues and boneLongitude Capital,New Enterprise Associates (NEA), Novo Ventures and Sanofi VenturesSeries A FinancingUnited States
NousCom$49 millionTo advance its pipeline of neoantigen cancer based immunotherapies to the clinicAbingworth, 5 AM Ventures, LSP and Versant VenturesSeries B FinancingSwitzerland
ImmusanT$40 millionFund a randomized Phase II clinical trial of escalating doses of Nexvax2 in celiac patients who possess the human leukocyte antigen-DQ2.5 (HLA-DQ2.5) immune recognition geneARCH Venture Partners and Vatera Healthcare Partners Series C FinancingUnited States
Exonics Therapeutics$40 millionFunds to support continued development of SingleCut CRISPR technology for Duchenne muscular dystrophyThe Column Group (TCG)Series A FinancingUnited States
ResTORbio$40 millionTo advance selective TORC1 inhibitors for aging-related diseases and conditionsOrbiMed, Fidelity Management & Research Company, Rock Springs Capital, Quan Capital and Nest BioSeries B FinancingUnited States
EOC Pharma$32 millionTo advance the development of EOC’s mid- and late-stage clinical pipeline, and to in-license additional late-stage oncology assets to bring new treatment options to patients in China.Taikang Investment Series B FinancingChina
Y-mAbs Therapeutics, Inc.$30 millionAn immunotherapy company discovering and developing innovative treatments for patients with cancerSofinnova and Scopia Capital ManagementEquity FinancingUnited States
Syapse $30 millionTo expand access to precision oncologyAscension Ventures, GE VenturesSeries D FinancingUnited States
X4 Pharmaceuticals$27 millionTo advance X4’s two lead drug candidates in clinical efficacy studies in immuno-oncology and a pivotal study in WHIM syndrome, a rare primary immunodeficiency diseaseCormorant Asset ManagementSeries B FinancingUnited States
Torque$25 millionTo develop a new class of Deep-Primed™ immune cell therapiesFlagship PioneeringSeries A FinancingUnited States
Fortuna Fix$25 millionTo conduct Phase I/IIa clinical trials in Parkinson's Disease and Spinal Cord Injury.Amgen’s VCSeries B FinancingCanada
Mavupharma $20 millionMavupharma is developing orally bioavailable, non-nucleotide modulators of the STING (stimulator of interferon genes) pathway to treat cancer and infectious diseasesFrazier Healthcare & Alpine BioVenturesSeries A FinancingUnited States
Locus Biosciences$19 millionDiscovery and development of a next generation CRISPR-Cas platform for precision antimicrobialsARTIS VenturesSeries A FinancingUnited States
Step Pharma$17.04 millionTo support advancement of first-in-class immunomodulators for autoimmune diseases towards clinical studiesKurma Partners, Bpifrance, Pontifax Series A FinancingFrance
Exicure, Inc.$11.2 millionTo advance gene regulatory and immunotherapeutic programs Luye Pharma Group, Eager Info Investments LTD, Knoll Capital Management and Purple Arch VenturesPrivate FinancingUnited States
Monopar Therapeutics Inc$9.7 millionTo initiate Validive® Phase III registration program for radiation induced severe oral mucositis in patients with head and neck cancerFundingUnited States
RDD Pharma$9.5 millionTo advance programs globally in anal fissure, fecal incontinence, radiation colitis/proctitis and pruritus ani.Pharmascience, Inc. & an international life science etc.Series B FinancingUnited States
Perlara $7.4 millionTo cure diseases thought too rare to matterPivotal Capital Alpha, Al-Hamra Group, Radical Investments etc.Equity FinancingUnited States
Check-Cap Ltd$2.5 millionClinical development of company's C-Scan® systemH.C. Wainwright & Co.Registered Direct OfferingIsrael
W5$1.33 millionTo enhance STEM (Science, Technology, Engineering & Maths) knowledge and understanding among the next generation of budding scientists through interactive learning.Almac GroupPartnership AgreementUnited Kingdom
Carmel Biosciences$0.5 millionTo sell and market PREXXARTAN® (valsartan) oral solution in the United States and its territoriesMedicure Inc.Exclusive U.S. Rights United States
Novartis Pharmaceuticals Corporation UndisclosedAcquisition of the U.S. rights to six well-known product lines from Novartis Pharmaceuticals Corporation (NPC): Lopressor® (metoprolol tartrate USP) but excluding Lopressor (metoprolol tartrate) Injection, Lopressor® HCT (metoprolol tartrate USP + hydrochlorothiazide USP), Lotensin® (benazepril HCl), Lotensin HCT® (benazepril HCl + hydrochlorothiazide USP), Parlodel® (bromocriptine mesylate USP) and Methergine® (methylergonovine maleate)Validus Pharmaceuticals & Wood Creek Capital Management, LLCExclusive U.S. Rights United States
Macroceutics UndisclosedArvinas will access Macroceutics’ DNA-Encoded chemical Libraries (“DEL”) to identify binders to multiple targetsArvinas LLCCollaboration United States
Moderna Therapeutics UndisclosedTo co-develop and co-commercialize relaxin mRNA therapeutic for heart failureAstraZenecaCollaboration United States
Decibel TherapeuticsUndisclosedTo discover and develop therapeutics for hearing loss and tinnitusRegeneronCollaboration United States
Vedanta BiosciencesUndisclosedTo analyze microbiome clinical data from interventional checkpoint inhibitor studies to identify microbiome signatures associated with response to immunotherapy and key mechanisms through which the gut microbiota modulate immunotherapeutic responses.Leiden University Medical Center & the University of South Alabama (USA) Mitchell Cancer InstituteCollaboration United States
Interleukin Genetics CLIA laboratoryUndisclosedThe addition will support the accelerated growth of Orig3n's direct-to-consumer genetic assessment businessOrig3n, IncAcquisition of Laboratory Business & Assets United States
Bio-Ops, Inc.UndisclosedTo help leaders of ELS companies make the major transformation from R&D to launch-ready commercial operationsSVA Consulting LLCMergerUnited States
Vigilare InternationalUndisclosedWCG expands portfolio to include top pharmacovigilance, drug safety solution providerWIRB Copernicus GroupAcquisition United States
PharmaterialsUndisclosedThe acquisition strengthens and expands Quotient’s formulation and manufacturing services footprint in the U.K., and further supports the growth of Quotient’s Translational Pharmaceutics® platformQuotient SciencesAcquisition United Kingdom
TGA Sciences, Inc.UndisclosedExpand Absorption Systems’ expertise in research and GxP assay development services and position Absorption Systems closer to customers in the expanding Boston/Cambridge biotech hub.Absorption SystemsAcquisition United States
LYPRO Biosciences assetsUndisclosedExpand CERENIS Therapeutics' HDL strategy into immuno-oncology and chemotherapeutic drug deliveryCERENIS Therapeutics Acquisition of TechnologyUnited States
BAG Health Care GmbHUndisclosedBAG Health Care GmbH’s Hygiene Monitoring business markets, distributes and services biological, cleaning and chemical indicators, as well as a range of infection prevention products sold into the same Central Sterile Supply customers. Mesa Laboratories, Inc.Acquisition of BusinessGermany
MDDX Research & InformaticsUndisclosedWith the acquisition comes MDDX’s best-in-class, cloud-based image submission technology, which will become the backbone of Bioclinica’s SMART solution.Bioclinica AcquisitionUnited States
Paganini BiopharmaUndisclosedTo add anti-EMP2 antibody to oncology pipeline OncoResponse Inc.AcquisitionUnited States
GlycotopeUndisclosedTo strengthen its position as a premier global player in the high-growth CDMO market, with continued investment in strategic assets and innovative technology platformsCelonic AGAcquisition of FacilityGermany
Centurion Medical ProductsUndisclosedTo have a full set of vascular access products that complement Medline's minor procedure tray offerings and its growing infection prevention focus.MedlineAcquisitionUnited States
Mayo ClinicUndisclosedOxistimulator technology is designed to reduce respiratory complications in post-surgical patients by preventing oxygen desaturationsMediPinesAcquisition of TechnologyUnited States
Euthymics Bioscience Inc.UndisclosedTwelve families of patents and patent applications including those underlying amitifadine, a serotonin-preferring triple reuptake inhibitor previously under phase 2 development by Euthymics. ETHISMOS RESEARCH INCAcquisition of Intellectual Property AssetsUnited States
Toxikon Europe N.V.UndisclosedAcquisition creates the leading global extractables and leachables lab testing platform to serve the pharmaceutical and medical device industriesSterigenics International LLCAcquisition of European Laboratory Business United States
Aralez Pharmaceuticals Inc.UndisclosedAuthorized generic version of Toprol-XL®Lannett Company, Inc. Exclusive U.S. Rights Canada
BiondVax Pharmaceuticals Ltd.UndisclosedTo evaluate the cell mediated immunity directly induced by BiondVax’s universal flu vaccine candidate M-001, as well as M-001’s priming effect to enhance the immunogenicity of current seasonal influenza vaccines. National Institute of Allergy and Infectious Diseases (NIAID) of (NIH)Clinical Trial Agreement Israel
Express Scripts UndisclosedTo provide Propeller's FDA-cleared digital solution to Express Scripts members using inhaler sensors and a mobile app to manage asthma or COPD.Propeller HealthCollaboration United States
ChemDiv Inc.UndisclosedTo advance research and development in the area of Sigma1 dysfunction associated with early onset neurodegenerative diseasesContext Therapeutics and Torrey Pines InvestmentCollaboration United States
ERS GenomicsUndisclosedCRISPR/Cas9 genome editing patents for tools and servicesCellecta, IncNon-Exclusive License Agreement Ireland
Solasia Pharma, K.K. UndisclosedClinical supply manufacture of the active pharmaceutical ingredient (API) darinaparsin, a novel mitochondrial-targeted agent developed for the treatment of various hematologic and solid cancersAlcamiManufacturing & Quality AgreementsChina
PledPharma AB UndisclosedTo develop and commercialize PledOx® in Asia Solasia Pharma K.K. License Agreement Sweden
NeurimmuneUndisclosedNeurimmune will conduct research to generate and validate human-derived monoclonal antibodies using its proprietary Reverse Translational MedicineTM (RTMTM) technology platformOno PharmaceuticalCollaboration Switzerland
PharmaMarUndisclosedTo commercialize the marine-derived anticancer drug Zepsyre® (lurbinectedin), if approved, in South KoreaBoryung PharmLicense Agreement Spain
CutisPharmaUndisclosedUnrestricted grant to the Foundation to further support its Colstridium Difficile awareness efforts.C Diff FoundationPartnership AgreementUnited States
Sunovion Pharmaceuticals Europe LtdUndisclosed To expand availability in Europe of Latuda® (generic name: lurasidone hydrochloride)Angelini License & Distribution AgreementUnited Kingdom
Elwyn Pharmacy GroupUndisclosedElwyn Pharmacy Group provides medications and supportive services for patients living with hard to treat disease states with the goal of achieving optimal patient outcomes.BioMatrix SpRxAcquisitionUnited States
ACON Laboratories, Inc.UndisclosedTo enter Glucose Monitoring Market with FDA-Cleared Products Glucose monitor, test strips and lancet device (the “GlucoGorx® Kit”)Innovus Pharma Agreement United States
CureVac AGUndisclosedFor developing CRISPR-based therapeutics in select disease areas, CureVac’s mRNA technology accessed to express Cas9 for in vivo liver-targeted therapiesnCRISPR Therapeutics, Casebia TherapeuticsCollaborationGermany
Aquila BioMedical Ltd.UndisclosedTo support its preclinical immuno-oncology programmes.Macrophage PharmaPartnership AgreementUnited States
Coghlan GroupUndisclosedCoghlan Group, is a leading materials management service company for clinical trials. Caligor Holdco, LLC.AcquisitionUnited States
HitGenUndisclosedDNA-encoded library based drug discovery research collaborationBoehringer IngelheimCollaboration China
Valeant Pharmaceuticals International, Inc.UndisclosedTo divest the Sprout Pharmaceuticals subsidiarySprout Pharmaceuticals Acquisition of BusinessCanada
Cue Biopharma, Inc.UndisclosedTo develop biologics engineered to selectively modulate disease-relevant T cell subsets for the treatment of autoimmune disease. Merck & Co.Collaboration & License AgreementUnited States
Gem PharmaceuticalsUndisclosedGPX-150, a broad spectrum phase II cancer drug candidateMonopar Therapeutics IncAcquisition of Drug CandidateUnited States
UndisclosedThe manufacturing of Russian biosimilars of rituximab and bevacizumab indicated for the treatment of cancer, approved in the first half of October 2017, will be based in Morocco and are planned to be marketed in Morocco, Senegal, Gabon, and Côte d’Ivoire.BIOCAD & Sothema LabsInvestment